Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014

Yoshino, Kiyoshi; Kurita, Tomoko; Takahashi, Fumiaki; Nagase, Satoru

doi:10.1111/jog.15284

Cited by 27 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we enrolled patients who were clinically diagnosed with ovarian cancer and could provide tumor tissue sample after surgery. Compared to the real-world distribution of each histology based on the JSOG annual report 22 , the proportion of mucinous carcinoma and low-grade serous carcinoma was smaller in the JGOG3025 trial. This may be due to the difficulty of preoperative diagnosis and tumor tissue sampling in mucinous and low-grade serous carcinomas.…”

Section: Discussionmentioning

confidence: 70%

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

Yoshihara

Baba

Shimada

et al. 2022

Preprint

View full text Add to dashboard Cite

The Cancer Genome Atlas has clarified that about 50% of high-grade serous ovarian cancer shows homologous recombination deficiency (HRD). However, the frequency of HRD in Japanese patients with ovarian cancer remains unclear. The aim of JGOG3025 study (NCT03159572) is to identify the frequency of HRD in Japanese patients with ovarian cancer. The JGOG3025 study is a multicenter collaborative prospective observational study involving 65 study sites throughout Japan. We recruited 996 patients who were clinically diagnosed with ovarian cancer before surgery from March 2017 to March 2019, and 701 patients were eligible for JGOG3025 criteria. We used frozen tumor tissues to extract DNA and performed targeted sequencing for 51 genes most of which are HR-associated genes in 701 ovarian cancers (298 high-grade serous, 189 clear cell, 135 endometrioid, 12 mucinous, 3 low-grade serous, and 64 others). HRD was defined as positive when at least one HR-associated gene was mutated. The frequencies of HRD and tumor BRCA1/2 mutation were 45.2% (317/701) and 18.5% (130/701) in the full analysis set (FAS), respectively. Next, we performed multivariate Cox proportional hazards regression analysis for progression-free survival (PFS) and overall survival (OS). Advanced-stage ovarian cancer patients with HRD had an adjusted hazard ratio of 0.72 (95%CI, 0.55-0.93) and 0.58 (95%CI, 0.39-0.87) for PFS and OS compared to those without HRD (p = 0.013 and 0.009). Our study demonstrated that mutations in HR-associated genes might be associated with their prognosis. Further study will be needed to investigate prognostic impact of each HR-associated gene in ovarian cancer. Clinical Trial Registration ID #: NCT03159572.

show abstract

Section: Discussionmentioning

confidence: 70%

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

Yoshihara

Baba

Shimada

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, we enrolled patients who were clinically diagnosed with ovarian cancer and could provide tumor tissue samples after surgery. Compared with the real‐world distribution of each histology based on the Japan Society of Obstetrics and Gynecology (JSOG) annual report, 33 the proportions of mucinous carcinoma and low‐grade serous carcinoma were smaller in the JGOG3025 trial. This may be due to the difficulty of preoperative diagnosis and tumor tissue sampling in mucinous and low‐grade serous carcinomas.…”

Section: Discussionmentioning

confidence: 90%

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study

et al. 2023

View full text Add to dashboard Cite

The Cancer Genome Atlas (TCGA) network has clarified that ~50% of high-grade serous ovarian cancers show homologous recombination deficiency (HRD). However, the frequency of HRD in Japanese patients with ovarian cancer remains unclear. We aimed to identify the frequency of HR-associated gene mutations in Japanese patients with ovarian cancer. The JGOG3025 study is a multicenter collaborative prospective observational study involving 65 study sites throughout Japan. We recruited 996 patients who were clinically diagnosed with ovarian cancer before surgery from March 2017 to March 2019, and 701 patients were eligible according to the criteria. We used frozen tumor tissues to extract DNA and performed next-generation sequencing for

show abstract

“…The number of patients with cervical cancer has been gradually increasing in Japan since 2000. Approximately 8000 patients were newly diagnosed with cervical cancer in 2018 [ 1 ]. In addition, the age-adjusted peak prevalence of cervical cancer has shifted to a younger age of approximately 40 years over the last decade.…”

Section: Introductionmentioning

confidence: 99%

Utility of vaginal vault cytology in the local recurrence of cervical cancer

et al. 2023

View full text Add to dashboard Cite

Background In Japan, 8000 women were newly diagnosed with cervical cancer in 2018. The healthcare insurance policy in Japan allows physicians to utilize vaginal volt cytology tests and serum biomarker measurement at every visit and imaging analysis at an adequate interval with screening for recurrence after initial treatment. However, the major surveillance guidelines published in the United States and European countries recommend focusing on pelvic examinations and symptom reviews to avoid unnecessary tests. This study aimed to reassess the benefits of standard surveillance methods adopted in this study by retrospective analysis. Methods From January 2009 to December 2015, the medical records of patients with recurrence who were initially diagnosed with International Federation of Gynecology and Obstetrics stage I–III cervical cancer were collected for this study. Clinicopathological data were statistically analyzed to identify significant factors. In the first 2 years, the patients underwent regular surveillance, including pelvic examination, serum tumor marker tests, vaginal vault cytology every 1–3 months, and imaging analysis at 6- to 12-month intervals. In the following 2 years, the patients received a regular check with the same methods every 4 months and an annual imaging analysis. Afterward, the patients had regular screening every 6 to 12 months. Results In the study period, 84 of the 981 patients experienced recurrence, and 88.1% had an asymptomatic recurrence. The disease-free interval was not related to the recurrence site. In univariate analysis, primary treatment, recurrence site, and diagnostic method were significant factors for survival outcomes. In contrast, multivariate analysis indicated that only primary treatment was a significant factor. In patients with local recurrence, multivariate analysis demonstrated that radiation as salvage therapy was an independent predictive factor for overall survival after recurrence. Conclusions In this retrospective study, routine imaging analysis and serum biomarker measurement did not contribute to patient prognosis after recurrence. In contrast, vaginal vault cytology can improve survival after recurrence in some patients. Tailored surveillance methods based on individual disease conditions and treatment modalities can improve post-recurrent survival outcomes.

show abstract

Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014

Cited by 27 publications

References 3 publications

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study

Utility of vaginal vault cytology in the local recurrence of cervical cancer

Contact Info

Product

Resources

About